Literature DB >> 7798333

Benzodiazepine receptor quantification in vivo in humans using [11C]flumazenil and PET: application of the steady-state principle.

N A Lassen1, P A Bartenstein, A A Lammertsma, M C Prevett, D R Turton, S K Luthra, S Osman, P M Bloomfield, T Jones, P N Patsalos.   

Abstract

Carbon-11-labeled flumazenil combined with positron emission tomography (PET) was used to measure the concentration (Bmax) of the benzodiazepine (Bz) receptor in the brain and its equilibrium dissociation constant (KD) for flumazenil in five normal subjects. The steady-state approach was used injecting the tracer as a bolus of high specific activity. In each subject two studies were carried out. The first study was performed at essentially zero receptor occupancy, the tracer alone study. The second study was performed at a steady-state receptor occupancy of about 50%, achieved by a prolonged constant infusion of nonlabeled ("cold") flumazenil starting 2h before the bolus tracer injection and continuing until the end of scanning period. In this second study the free concentration of unmetabolized flumazenil in plasma water was measured in multiple blood samples. The observed tissue and plasma tracer curves, calibrated in the same units of radioactivity per millimeter, were analyzed in two ways: (a) by the noncompartmental (stochastic) approach making no assumptions regarding number of compartments in the tissue, and (b) by the single-compartment approach assuming rapid exchange (mixing) of tracer between all tissue compartments. The noncompartmental and the compartmental analyses gave essentially the same values for the distribution volume of the tracer, the parameter used for quantitation of the Bz receptor. As the compartmental approach could be applied to a shorter observation period (60 min instead of 120 min) it was preferred. The five subjects had a mean KD value of 12 nM/L of water and Bmax values of the grey matter ranging from 39 +/- 11 in thalamus to 120 +/- 14 nM/L of brain in occipital cortex. Most previous studies have been based on the pseudoequilibrium approach using the brain stem as a receptor-free reference region. This yields practically the same KD but lower Bmax values than the steady-state approach presented here.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7798333     DOI: 10.1038/jcbfm.1995.17

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  65 in total

1.  In vivo and in vitro validation of reference tissue models for the mGluR(5) ligand [(11)C]ABP688.

Authors:  David Elmenhorst; Luciano Minuzzi; Antonio Aliaga; Jared Rowley; Gassan Massarweh; Mirko Diksic; Andreas Bauer; Pedro Rosa-Neto
Journal:  J Cereb Blood Flow Metab       Date:  2010-06-09       Impact factor: 6.200

2.  In vivo positron emission tomography imaging with [¹¹C]ABP688: binding variability and specificity for the metabotropic glutamate receptor subtype 5 in baboons.

Authors:  Christine DeLorenzo; Matthew S Milak; Kathleen G Brennan; J S Dileep Kumar; J John Mann; Ramin V Parsey
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-29       Impact factor: 9.236

3.  Evaluation of [(11)C]MRB for assessment of occupancy of norepinephrine transporters: Studies with atomoxetine in non-human primates.

Authors:  Jean-Dominique Gallezot; David Weinzimmer; Nabeel Nabulsi; Shu-Fei Lin; Krista Fowles; Christine Sandiego; Timothy J McCarthy; R Paul Maguire; Richard E Carson; Yu-Shin Ding
Journal:  Neuroimage       Date:  2010-09-30       Impact factor: 6.556

4.  Population pharmacokinetic analysis for simultaneous determination of B (max) and K (D) in vivo by positron emission tomography.

Authors:  Lia C Liefaard; Bart A Ploeger; Carla F M Molthoff; Ronald Boellaard; Adriaan A Lammertsma; Meindert Danhof; Rob A Voskuyl
Journal:  Mol Imaging Biol       Date:  2005 Nov-Dec       Impact factor: 3.488

5.  Exploring occupancy of the histamine H3 receptor by pitolisant in humans using PET.

Authors:  Pablo Rusjan; Pamela Sabioni; Patricia Di Ciano; Esmaeil Mansouri; Isabelle Boileau; Alexia Laveillé; Marc Capet; Thierry Duvauchelle; Jean-Charles Schwartz; Philippe Robert; Bernard Le Foll
Journal:  Br J Pharmacol       Date:  2020-05-23       Impact factor: 8.739

6.  Kinetic Analysis and Quantification of [¹¹C]Martinostat for in Vivo HDAC Imaging of the Brain.

Authors:  Hsiao-Ying Wey; Changning Wang; Frederick A Schroeder; Jean Logan; Julie C Price; Jacob M Hooker
Journal:  ACS Chem Neurosci       Date:  2015-03-25       Impact factor: 4.418

Review 7.  Classics in chemical neuroscience: diazepam (valium).

Authors:  Nicholas E Calcaterra; James C Barrow
Journal:  ACS Chem Neurosci       Date:  2014-02-27       Impact factor: 4.418

8.  18F-ASEM, a radiolabeled antagonist for imaging the α7-nicotinic acetylcholine receptor with PET.

Authors:  Andrew G Horti; Yongjun Gao; Hiroto Kuwabara; Yuchuan Wang; Sofya Abazyan; Robert P Yasuda; Thao Tran; Yingxian Xiao; Niaz Sahibzada; Daniel P Holt; Kenneth J Kellar; Mikhail V Pletnikov; Martin G Pomper; Dean F Wong; Robert F Dannals
Journal:  J Nucl Med       Date:  2014-02-20       Impact factor: 10.057

9.  Further evaluation of the carbon11-labeled D(2/3) agonist PET radiotracer PHNO: reproducibility in tracer characteristics and characterization of extrastriatal binding.

Authors:  Alice Egerton; Ella Hirani; Rabia Ahmad; David R Turton; Diana Brickute; Lula Rosso; Oliver D Howes; Sajinder K Luthra; Paul M Grasby
Journal:  Synapse       Date:  2010-04       Impact factor: 2.562

10.  Investigation of Proposed Activity of Clarithromycin at GABAA Receptors Using [(11)C]Flumazenil PET.

Authors:  Peter J H Scott; Xia Shao; Timothy J Desmond; Brian G Hockley; Phillip Sherman; Carole A Quesada; Kirk A Frey; Robert A Koeppe; Michael R Kilbourn; Nicolaas I Bohnen
Journal:  ACS Med Chem Lett       Date:  2016-06-01       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.